ConductScience.org, home

Paper29637482

Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.

Su J and 2 others. Clin Rheumatol, 2018. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. Papers, record 29637482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29637482

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis.
PubMed
Journal
Clin Rheumatol
PubMed
Year
2018
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.34
iCite
Revised in PubMed
2025-06-23
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Su JJiang
2Long LLi
3Zou KKunhttps://orcid.org/0000-0002-2175-2231

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
Hepatitis B virusMajor topic
Hepatitis B, ChronicMajor topic
Rheumatic DiseasesMajor topic
Virus ActivationMajor topic
Antirheumatic Agents
Humans
Lamivudine
Randomized Controlled Trials as Topic
Reproducibility of Results
Risk
Sensitivity and Specificity

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128128861Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.Hepatology2017https://conductscience.org/library/papers/28128861PubMed
226819537Treatment of chronic hepatitis B patients with tyrosine-methionine-aspartate-aspartate mutations.World J Gastroenterol2016https://conductscience.org/library/papers/26819537PubMed
322460162Barriers to treatment of hepatitis B in an urban Chinatown community.J Clin Gastroenterol2012https://conductscience.org/library/papers/22460162PubMed
425678179The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.J Formos Med Assoc2015https://conductscience.org/library/papers/25678179PubMed
518302293A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial.Hepatology2008https://conductscience.org/library/papers/18302293PubMed
619729084Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.Vaccine2009https://conductscience.org/library/papers/19729084PubMed
716440366Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.Hepatology2006https://conductscience.org/library/papers/16440366PubMed
827291888Prevention of Hepatitis B reactivation in the setting of immunosuppression.Clin Mol Hepatol2016https://conductscience.org/library/papers/27291888PubMed
918378948Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.Ann Intern Med2008https://conductscience.org/library/papers/18378948PubMed
1011722410Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.Br J Haematol2001https://conductscience.org/library/papers/11722410PubMed
11265459402015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Arthritis Rheumatol2016https://conductscience.org/library/papers/26545940PubMed
1225447850American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.Gastroenterology2015https://conductscience.org/library/papers/25447850PubMed
1326057738Prophylactic Effect of Lamivudine for Chemotherapy-Induced Hepatitis B Reactivation in Breast Cancer: A Meta-Analysis.PLoS One2015https://conductscience.org/library/papers/26057738PubMed
1427450506Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.Int J Clin Pharm2016https://conductscience.org/library/papers/27450506PubMed
1525199680Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: a systematic review and meta-analysis.Clin Res Hepatol Gastroenterol2015https://conductscience.org/library/papers/25199680PubMed
1622273662Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity.Vaccine2012https://conductscience.org/library/papers/22273662PubMed
1719714720Chronic hepatitis B: update 2009.Hepatology2009https://conductscience.org/library/papers/19714720PubMed
1812774010Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma.Hepatology2003https://conductscience.org/library/papers/12774010PubMed
1925532827
Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.
BMC Musculoskelet Disord2014https://conductscience.org/library/papers/25532827PubMed
2025114684HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis.Int J Rheumatol2014https://conductscience.org/library/papers/25114684PubMed

See all 34 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42370076Low value of routine serological screening for hepatitis B in patients with rheumatoid arthritis starting rituximab therapy in a nonendemic region.EULAR Rheumatol Open2026https://conductscience.org/library/papers/42370076PubMed
36323488Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases.RMD Open2022https://conductscience.org/library/papers/36323488PubMed
34200522Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update.J Clin Med2021https://conductscience.org/library/papers/34200522PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29637482

GET https://conductscience.org/api/papers/v1/29637482/references?page=2